Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity

Overview

Journal Microbiol Mol Biol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2016 Oct 28

PMID 27784796

Citations 60

Authors

Laura A VanBlargan

Leslie Goo

Theodore C Pierson

Affiliations

Soon will be listed here.

Abstract

The antibody response plays a key role in protection against viral infections. While antiviral antibodies may reduce the viral burden via several mechanisms, the ability to directly inhibit (neutralize) infection of cells has been extensively studied. Eliciting a neutralizing-antibody response is a goal of many vaccine development programs and commonly correlates with protection from disease. Considerable insights into the mechanisms of neutralization have been gained from studies of monoclonal antibodies, yet the individual contributions and dynamics of the repertoire of circulating antibody specificities elicited by infection and vaccination are poorly understood on the functional and molecular levels. Neutralizing antibodies with the most protective functionalities may be a rare component of a polyclonal, pathogen-specific antibody response, further complicating efforts to identify the elements of a protective immune response. This review discusses advances in deconstructing polyclonal antibody responses to flavivirus infection or vaccination. Our discussions draw comparisons to HIV-1, a virus with a distinct structure and replication cycle for which the antibody response has been extensively investigated. Progress toward deconstructing and understanding the components of polyclonal antibody responses identifies new targets and challenges for vaccination strategies.

Citing Articles

Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SA-14-2.

Song B, Frank J, Yun S, Julander J, Mason J, Polejaeva I Int J Mol Sci. 2025; 26(1.

PMID: 39796052 PMC: 11720029. DOI: 10.3390/ijms26010195.

Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures.

Gonzalez-Carmona M, Schmitz A, Berger M, Baier L, Gorny J, Sadeghlar F Int J Mol Sci. 2025; 25(24.

PMID: 39769379 PMC: 11728159. DOI: 10.3390/ijms252413613.

FcγRIIa-mediated antibody-dependent uptake of SARS-CoV-2 enhances IL-6 expression of monocytes.

Mese K, Maguilla Rosado E, Luder C, Abdel-Moneim A, Jordan P, Schwanbeck J Eur J Microbiol Immunol (Bp). 2024; 14(4):380-391.

PMID: 39680053 PMC: 11836651. DOI: 10.1556/1886.2024.00109.

Surface Display of Duck Hepatitis A Virus Type 1 VP1 Protein on Bacillus subtilis Spores Elicits Specific Systemic and Mucosal Immune Responses on Mice.

Chen B, Yang Y, Wang Z, Dai X, Cao Y, Zhang M Probiotics Antimicrob Proteins. 2024; .

PMID: 39002060 DOI: 10.1007/s12602-024-10323-2.

A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy.

Chong A, Brenner N, Jimenez-Kaufmann A, Cortes A, Hill M, Littlejohns T Am J Hum Genet. 2024; 111(2):295-308.

PMID: 38232728 PMC: 10870136. DOI: 10.1016/j.ajhg.2023.12.013.

References

Mukhopadhyay S, Kim B, Chipman P, Rossmann M, Kuhn R . Structure of West Nile virus. Science. 2003; 302(5643):248. DOI: 10.1126/science.1089316. View

Thyagarajan B, Bloom J . The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. Elife. 2014; 3. PMC: 4109307. DOI: 10.7554/eLife.03300. View

Diskin R, Scheid J, Marcovecchio P, West Jr A, Klein F, Gao H . Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 2011; 334(6060):1289-93. PMC: 3232316. DOI: 10.1126/science.1213782. View

Fibriansah G, Ibarra K, Ng T, Smith S, Tan J, Lim X . DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 2015; 349(6243):88-91. PMC: 4672004. DOI: 10.1126/science.aaa8651. View

Chojnacki J, Staudt T, Glass B, Bingen P, Engelhardt J, Anders M . Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science. 2012; 338(6106):524-8. DOI: 10.1126/science.1226359. View

Cherrier M, Kaufmann B, Nybakken G, Lok S, Warren J, Chen B . Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 2009; 28(20):3269-76. PMC: 2771083. DOI: 10.1038/emboj.2009.245. View

Robertson D, Anderson J, Bradac J, Carr J, Foley B, FUNKHOUSER R . HIV-1 nomenclature proposal. Science. 2000; 288(5463):55-6. DOI: 10.1126/science.288.5463.55d. View

Hicar M, Chen X, Briney B, Hammonds J, Wang J, Kalams S . Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. J Acquir Immune Defic Syndr. 2010; 54(3):223-35. PMC: 2930513. DOI: 10.1097/QAI.0b013e3181dc98a3. View

Moore P, Ranchobe N, Lambson B, Gray E, Cave E, Abrahams M . Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009; 5(9):e1000598. PMC: 2742164. DOI: 10.1371/journal.ppat.1000598. View

10.

Mansky L, Temin H . Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995; 69(8):5087-94. PMC: 189326. DOI: 10.1128/JVI.69.8.5087-5094.1995. View

11.

Manz R, Thiel A, Radbruch A . Lifetime of plasma cells in the bone marrow. Nature. 1997; 388(6638):133-4. DOI: 10.1038/40540. View

12.

Pancera M, Shahzad-Ul-Hussan S, Doria-Rose N, McLellan J, Bailer R, Dai K . Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol. 2013; 20(7):804-13. PMC: 4046252. DOI: 10.1038/nsmb.2600. View

13.

Scheid J, Mouquet H, Feldhahn N, Seaman M, Velinzon K, Pietzsch J . Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009; 458(7238):636-40. DOI: 10.1038/nature07930. View

14.

Smith T, Olson N, Cheng R, Liu H, Chase E, Lee W . Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. J Virol. 1993; 67(3):1148-58. PMC: 237479. DOI: 10.1128/JVI.67.3.1148-1158.1993. View

15.

Jarmer J, Zlatkovic J, Tsouchnikas G, Vratskikh O, Strauss J, Aberle J . Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J Virol. 2014; 88(23):13845-57. PMC: 4248988. DOI: 10.1128/JVI.02086-14. View

16.

Burton D, Ahmed R, Barouch D, Butera S, Crotty S, Godzik A . A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012; 12(4):396-407. PMC: 3513329. DOI: 10.1016/j.chom.2012.09.008. View

17.

Diamond M, Pierson T, Fremont D . The structural immunology of antibody protection against West Nile virus. Immunol Rev. 2008; 225:212-25. PMC: 2646609. DOI: 10.1111/j.1600-065X.2008.00676.x. View

18.

Arnold J, Wormald M, Sim R, Rudd P, Dwek R . The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2006; 25:21-50. DOI: 10.1146/annurev.immunol.25.022106.141702. View

19.

Davies D, Cohen G . Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A. 1996; 93(1):7-12. PMC: 40169. DOI: 10.1073/pnas.93.1.7. View

20.

Wei X, Decker J, Wang S, Hui H, Kappes J, Wu X . Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. DOI: 10.1038/nature01470. View